Can Sevelamer Be Given in Children?
Yes, sevelamer can be given to children with chronic kidney disease (CKD) and has proven efficacy and safety in pediatric populations. According to KDOQI guidelines, sevelamer is the only calcium- and aluminum-free phosphate binder with demonstrated efficacy and safety in children, having been assessed in randomized controlled trials involving 47 children 1.
Evidence Supporting Pediatric Use
The KDOQI Clinical Practice Guidelines (2009) explicitly state that when total intestinal calcium load becomes excessive or hypercalcemia exists with calcium-containing phosphate binders, these should be replaced by calcium- and aluminum-free phosphate binders, with sevelamer being the only such agent with proven pediatric efficacy and safety 1.
Clinical Trial Data in Children
Two key randomized controlled trials establish sevelamer's pediatric use:
Hemodialysis study: 29 hemodialyzed children received either sevelamer or calcium carbonate over 8 months. Phosphorus control was equivalent between groups, but the sevelamer group had significantly lower serum calcium levels, lower calcium-phosphorus product, and fewer hypercalcemia episodes 1, 2.
CKD stages 3-4 crossover study: 18 children with CKD stages 3-4 or 5D received both treatments in 8-week periods. Phosphorus and PTH control were similar, but calcium acetate caused more frequent hypercalcemia. Notably, sevelamer reduced LDL cholesterol by 34% 1, 2.
Clinical Indications for Pediatric Use
Sevelamer should be used in children when:
- Hypercalcemia develops on calcium-based phosphate binders
- Excessive total intestinal calcium load exists, regardless of serum calcium level 1
- Hyperphosphatemia persists despite dietary restriction and calcium-based binders
- Vascular calcification risk is a concern (extrapolated from adult data showing attenuation of arterial calcifications) 1
Important Caveats and Monitoring
Metabolic Acidosis Risk
A critical pitfall with sevelamer hydrochloride is the increased incidence of metabolic acidosis, which is particularly concerning in children as it can impair growth 1, 2. The newer sevelamer carbonate formulation addresses this issue and has been shown to increase serum bicarbonate in pediatric dialysis patients 3. When using sevelamer hydrochloride, monitor acid-base status closely and consider switching to sevelamer carbonate if acidosis develops.
Dosing Considerations
While the FDA label does not provide specific pediatric dosing, clinical studies have used:
- Initial doses of 100-130 mg/kg/day divided every 8 hours 4
- Mean doses of 117 mg/kg/day in resistant hyperphosphatemia 5
- Titration based on phosphorus response, similar to adult protocols
Pill Burden Challenge
The major limitation is the substantial pill burden - children must swallow several large tablets with each meal, which can seriously compromise adherence and quality of life 1. This requires individualized assessment of whether the benefits outweigh the impact on daily functioning. Packet formulations may improve tolerability in children unable to swallow tablets.
Advantages Over Calcium-Based Binders
Sevelamer offers several benefits in pediatric CKD-MBD management:
- Lower hypercalcemia risk - critical for growing children
- Reduced calcium-phosphorus product - decreases vascular calcification risk
- Lipid-lowering effects - 34% reduction in LDL cholesterol 2
- No aluminum exposure - avoids neurotoxicity concerns in children with renal disease
Practical Implementation
Start sevelamer when calcium-based binders cause hypercalcemia or when total calcium intake exceeds safe limits. Monitor serum phosphorus, calcium, PTH, and bicarbonate every 2 weeks initially, adjusting doses as needed 2. Consider sevelamer carbonate over hydrochloride to avoid metabolic acidosis 3. Ensure involvement of an experienced pediatric dietitian for comprehensive phosphorus management 1.
The evidence consistently supports sevelamer as a safe and effective phosphate binder in children with CKD, particularly when calcium-based alternatives are contraindicated or ineffective.